ALLMedicine™ Blastic Plasmacytoid Dendritic Cell Center
Research & Reviews 242 results
https://doi.org/10.1182/bloodadvances.2022007879
Blood Advances; Beird HC, Yin CC et. al.
Jan 24th, 2023 - TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.|2023|Beird HC,Yin CC,Khoury JD,Pierce SR,Abbas HA,|
https://doi.org/10.1111/bjh.18632
British Journal of Haematology; El Hussein S, Wang W
Jan 7th, 2023 - In this article, we describe three broad pathologic presentations of plasmacytoid dendritic cells (pDCs) that may be encountered in clinical practice, in which an association between pDCs and myeloid neoplasms is identified: (1) myeloid neoplasms ...
https://clinicaltrials.gov/ct2/show/NCT02159495
Jan 5th, 2023 - PRIMARY OBJECTIVES: I. To examine the anti-tumor activity and safety of administering ex vivo expanded T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a co-stimulatory CD123-specific chimeric anti...
https://doi.org/10.1038/s41375-022-01782-z
Leukemia Bruch PM, Dietrich S et. al.
Dec 23rd, 2022 - Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, ...
https://clinicaltrials.gov/ct2/show/NCT05430971
Dec 23rd, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The fi...
Drugs 2 results see all →
Clinicaltrials.gov 13 results
https://clinicaltrials.gov/ct2/show/NCT02159495
Jan 5th, 2023 - PRIMARY OBJECTIVES: I. To examine the anti-tumor activity and safety of administering ex vivo expanded T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a co-stimulatory CD123-specific chimeric anti...
https://clinicaltrials.gov/ct2/show/NCT05430971
Dec 23rd, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The fi...
https://clinicaltrials.gov/ct2/show/NCT05074316
Nov 22nd, 2022 - During recent years, considerable progress has been made in deciphering the molecular genetic and epigenetic basis of myeloid neoplasms and in defining new diagnostic and prognostic as well as predictive markers. Myeloid neoplasms are categorized ...
https://clinicaltrials.gov/ct2/show/NCT05476770
Nov 15th, 2022 - Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to exami...
https://clinicaltrials.gov/ct2/show/NCT04216524
Sep 23rd, 2022 - PRIMARY OBJECTIVE: I. To evaluate progression-free survival (PFS) at 12 months of venetoclax (VEN) in combination with chemotherapy and SL-401 (tagraxofusp [TAG]) in patients with newly diagnosed blastic plasmacytoid dendritic cell neoplasm (BPDCN...
News 65 results
https://www.onclive.com/view/dr-wang-on-the-current-treatment-options-for-bpdcn
Nov 21st, 2022 - Eunice Wang, MD, chief the Leukemia Service, the Department of Medicine, Roswell Park Comprehensive Cancer Center, discusses the current treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Up-front treatment for patients w...
https://www.medpagetoday.com/hematologyoncology/othercancers/100523
Sep 2nd, 2022 - "Nothing is guaranteed." NFL head coach Ron Rivera of the Washington Commanders talks about how cancer changes a person's life. (ESPN) The FDA announced that Intera Oncology has issued a recall for the Intera 3000 infusion pump following reports o...
https://www.onclive.com/view/frontline-pivekimab-sunirine-demonstrates-significant-activity-in-blastic-plasmacytoid-dendritic-cell-neoplasm
Aug 31st, 2022 - First-line treatment with pivekimab sunirine (IMGN632) generated responses with favorable tolerability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data from the phase 2 CADENZA trial (NCT03386513).1 Among...
https://www.mdedge.com/dermatology/article/252525/dermatopathology/isolated-nodule-and-generalized-lymphadenopathy
Yahya Daneshbod, MD, Michael Greas, MD et. al.
Mar 8th, 2022 - The Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm A diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was rendered. Subsequent needle core biopsy of a left axillary lymph node as well as bone marrow aspiration and biopsy.
https://www.onclive.com/view/tagraxofusp-and-hyper-cvad-represent-treatment-options-for-patients-with-bpdcn
Feb 3rd, 2022 - Despite the rarity of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2 studies examining treatment options for the disease produced encouraging results and safety data, according to Naveen Pemmaraju, MD. Pemmaraju p...